Meeting
2018 Genitourinary Cancers Symposium
Randomized, multicentre phase II trial of the sequencing of radium-223 and docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC).
Authors
Vincenza Conteduca
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy
Vincenza Conteduca , Stefano Severi , Stefania Gori , Luca Galli , Michele Aieta , Gaetano Facchini , Cristina Masini , Donatello Gasparro , Lucia Fratino , Susanne Baier , Emanuela Scarpi , Sara Testoni , Valeria Sirna , Linda Valmorri , Bernadette Vertogen , Giovanni Paganelli , Ugo De Giorgi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT03230734
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr TPS396)
DOI
10.1200/JCO.2018.36.6_suppl.TPS396
Abstract #
TPS396
Poster Bd #
M16
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
LORIKEET: A phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Sumit Kumar Subudhi
Poster
2023 ASCO Genitourinary Cancers Symposium
Characteristics of long-term responder (LTR) patients (pts) treated with androgen-receptor signaling inhibitors (ARSI) as a first-line treatment for metastatic castration-resistant prostate cancer (mCRPC): Real-world evidence from four high-volume institutions.
First Author: Orazio Caffo
Poster
2022 ASCO Annual Meeting
A phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Ulka N. Vaishampayan
Poster
2021 ASCO Annual Meeting
First results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC).
First Author: Kim van der Zande